Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$72.44
-0.1%		$80.65
$48.78
▼
$93.42
$14.16B0.971.91 million shs1.77 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$56.12
-2.3%		$55.35
$33.76
▼
$59.72
$13.91B0.421.95 million shs2.92 million shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$24.62
-5.8%		$28.92
$11.30
▼
$31.74
$3.13B0.811.20 million shs4.28 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.55
+3.2%		$14.50
$12.07
▼
$29.23
$14.00B-1.246.33 million shs4.27 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-3.21%-10.80%+8.44%+36.78%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%-4.90%+10.89%+5.63%+48.86%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.00%-17.01%-14.62%+3.25%+109.55%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%-0.28%+25.36%+25.27%-0.28%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$72.44
-0.1%		$80.65
$48.78
▼
$93.42
$14.16B0.971.91 million shs1.77 million shs
Exelixis, Inc. stock logo
EXEL
Exelixis
$56.12
-2.3%		$55.35
$33.76
▼
$59.72
$13.91B0.421.95 million shs2.92 million shs
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$24.62
-5.8%		$28.92
$11.30
▼
$31.74
$3.13B0.811.20 million shs4.28 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$17.55
+3.2%		$14.50
$12.07
▼
$29.23
$14.00B-1.246.33 million shs4.27 million shs
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%-3.21%-10.80%+8.44%+36.78%
Exelixis, Inc. stock logo
EXEL
Exelixis
0.00%-4.90%+10.89%+5.63%+48.86%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.00%-17.01%-14.62%+3.25%+109.55%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
0.00%-0.28%+25.36%+25.27%-0.28%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.83
Moderate Buy$102.6141.65% Upside
Exelixis, Inc. stock logo
EXEL
Exelixis
2.38
Hold$50.07-10.79% Downside
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
2.62
Moderate Buy$38.3055.54% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.47
Hold$25.9147.63% Upside

Current Analyst Ratings Breakdown

Latest RCUS, BBIO, EXEL, and SMMT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2026
Exelixis, Inc. stock logo
EXEL
Exelixis
William Blair logo
William Blair
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform
9/11/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/10/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (D-) ➝ Sell (D)
9/10/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/9/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
Summit Redstone logo
Summit Redstone
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$25.00
9/8/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$33.00
9/8/2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$35.00 ➝ $40.00
9/3/2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
9/2/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/2/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$120.00
9/1/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$96.00 ➝ $110.00
(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$502.08M28.21N/AN/A($10.77) per share-6.73
Exelixis, Inc. stock logo
EXEL
Exelixis
$2.32B5.99$3.03 per share18.54$8.06 per share6.96
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
$247M12.69N/AN/A$5.84 per share4.22
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/A$0.85 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Exelixis, Inc. stock logo
EXEL
Exelixis
$782.57M$3.1817.6515.091.6735.33%42.17%31.76%11/3/2026 (Estimated)
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$353M-$3.90N/AN/AN/A-393.16%-89.54%-45.61%10/27/2026 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$1.08B-$1.12N/AN/AN/AN/A-168.94%-141.92%10/19/2026 (Estimated)

Latest RCUS, BBIO, EXEL, and SMMT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/5/2026Q2 2026
Exelixis, Inc. stock logo
EXEL
Exelixis
$0.8530$0.91+$0.0570$0.8438$636.40 million$628.69 million
8/5/2026Q2 2026
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
-$0.8912-$0.72+$0.1712-$0.72$21.98 million$41.00 million
7/23/2026Q2 2026
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.2744-$0.28-$0.0056-$0.28$0.11 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Exelixis, Inc. stock logo
EXEL
Exelixis
N/AN/AN/AN/AN/A
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Exelixis, Inc. stock logo
EXEL
Exelixis
N/A
3.46
3.38
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
0.22
3.82
3.82
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
6.96
6.96

Institutional Ownership

CompanyInstitutional Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Exelixis, Inc. stock logo
EXEL
Exelixis
85.27%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
92.89%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%

Insider Ownership

CompanyInsider Ownership
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Exelixis, Inc. stock logo
EXEL
Exelixis
2.60%
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
7.60%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
83.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
839195.49 million167.67 millionOptionable
Exelixis, Inc. stock logo
EXEL
Exelixis
1,077247.78 million241.34 millionOptionable
Arcus Biosciences, Inc. stock logo
RCUS
Arcus Biosciences
601127.33 million117.66 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
265797.75 million131.63 millionOptionable

Recent News About These Companies

Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in China
 |  businesswire.comhttps://www.businesswire.com/news/home/20260913549808/en/ivonescimab-monotherapy-demonstrates-a-statistically-significant-clinically-meaningful-benefit-compared-to-pembrolizumab-monotherapy-in-pd-l1-positive-advanced-nsclc-in-akeso%e2%80%99s-harmoni-2-study-conducted-in-china/
Hsbc Holdings PLC Purchases Shares of 120,560 Summit Therapeutics PLC $SMMT
September 12 at 3:14 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-hsbc-holdings-plc-purchases-shares-of-120560-summit-therapeutics-plc-smmt-2026-09-12/
Summit Therapeutics PLC (SMMT)
September 10 at 12:36 AM  |  fr.investing.comhttps://fr.investing.com/equities/summit-therapeutics-plc-news
Summit Therapeutics Shares Rise After Upgrade From Jefferies
September 9, 2026  |  marketscreener.comM
Summit Therapeutics shares gain after Jefferies upgrades stock to buy
September 9, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/summit-therapeutics-shares-gain-after-jefferies-upgrades-stock-to-buy/ar-AA2bSSP1
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - Time to Buy?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-shares-gap-up-time-to-buy-2026-09-09/
Summit Therapeutics PLC $SMMT Shares Bought by Wellington Management Group LLP
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-summit-therapeutics-plc-smmt-shares-bought-by-wellington-management-group-llp-2026-09-09/
Summit (SMMT) Says Akeso Reported a HARMONi-2 Overall-Survival Benefit Against Pembrolizumab
September 8, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/summit-smmt-says-akeso-reported-a-harmoni-2-overall-survival-benefit-against-pembrolizumab-1827424/
Summit Therapeutics (SMMT) Soars 28% on Ivonescimab Progress
September 7, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/summit-therapeutics-smmt-soars-28-on-ivonescimab-progress-1829526/
Seven Fleet Capital Management LP Acquires Shares of 73,300 Summit Therapeutics PLC $SMMT
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-seven-fleet-capital-management-lp-acquires-shares-of-73300-summit-therapeutics-plc-smmt-2026-09-05/
Bank of New York Mellon Corp Takes $6.28 Million Position in Summit Therapeutics PLC $SMMT
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-takes-628-million-position-in-summit-therapeutics-plc-smmt-2026-09-05/
Summit Therapeutics (NASDAQ:SMMT) Rating Increased to Hold at Wall Street Zen
September 5, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31003806
Summit Therapeutics (NASDAQ:SMMT) Raised to Hold at Wall Street Zen
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-summit-therapeutics-nasdaq-smmt-raised-to-hold-at-wall-street-zen-2026-09-05/
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in China
September 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2985150/smmt-stock-soars-on-nsclc-drug-survival-data-beating-keytruda-in-china?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2985150
Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S.
September 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4942941-summit-therapeutics-the-high-stakes-of-translating-china-clinical-data-to-the-us
Summit packs a punch for Merck's Keytruda — but not everyone is sold
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/summit-packs-a-punch-for-mercks-keytruda-but-not-everyone-is-sold/ar-AA2bw59t
Summit Therapeutics Stock Rises 11%
September 3, 2026  |  rttnews.comhttps://www.rttnews.com/3688357/summit-therapeutics-stock-rises-11.aspx
Better cancer therapy than Keytruda? Summit Therapeutics partner's Ivonescimab outperforms in lung cancer study
September 3, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/better-cancer-therapy-than-keytruda-summit-therapeutics-partners-ivonescimab-outperforms-in-lung-cancer-study/ar-AA2bvX1i
Summit Therapeutics (NASDAQ:SMMT) Shares Gap Up - What's Next?
September 3, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-summit-therapeutics-nasdaq-smmt-shares-gap-up-whats-next-2026-09-03/
November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Bet
September 3, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4942687-november-14-is-make-or-break-moment-for-summit-therapeuticss-cancer-bet
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in China
September 2, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260902840786/en/Ivonescimab-Monotherapy-Demonstrates-Statistically-Significant-Overall-Survival-Benefit-Compared-to-Pembrolizumab-Monotherapy-in-PD-L1-Positive-Advanced-NSCLC-in-HARMONi-2-Study-Conducted-by-Akeso-in-China/

New MarketBeat Followers Over Time

Media Sentiment Over Time

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$72.44 -0.06 (-0.08%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$70.25 -2.19 (-3.02%)
As of 09/11/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Exelixis stock logo

Exelixis NASDAQ:EXEL

$56.12 -1.31 (-2.28%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$56.12 0.00 (0.00%)
As of 09/11/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Arcus Biosciences stock logo

Arcus Biosciences NYSE:RCUS

$24.62 -1.53 (-5.84%)
Closing price 09/11/2026 03:58 PM Eastern
Extended Trading
$24.41 -0.22 (-0.89%)
As of 09/11/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$17.55 +0.55 (+3.24%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$17.66 +0.11 (+0.63%)
As of 09/11/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas